Get started
Author

Foivos Sokratis Lazaris

Observed names: Foivos Lazaris, Foivos S. Lazaris, Lazaris, Foivos S, Lazaris, Foivos Sokratis
ORCID: 0000-0003-4292-8723
Observed ORCID: 0000-0003-4292-8723
OpenAlex ID: A5015780086
Non‐Natural MUC1 Glycopeptide Homogeneous Cancer Vaccine with Enhanced Immunogenicity and Therapeutic Activity
2024 · Ana Guerreiro, Ismael Compañón, et al. · Angewandte Chemie International Edition · 29
PDF
Structure-Guided Approach for the Development of MUC1-Glycopeptide-Based Cancer Vaccines with Predictable Responses
2023 · Iris A. Bermejo, Ana Guerreiro, et al. · JACS Au · 19
Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer
2019 · Dimitra-Ioanna Lampropoulou, Gerasimos Aravantinos, et al. · Cancer Biomarkers · 14
Enhancing Cancer Vaccine Efficacy: Backbone Modification with β-Amino Acids Alters the Stability and Immunogenicity of MUC1-Derived Glycopeptide Formulations
2025 · Ruslan Gibadullin, Óscar Suárez, et al. · JACS Au · 11
PDF
In vitro effect of hyperthermic Ag and Au Fe3O4 nanoparticles in cancer cells.
2020 · Hector Katifelis, Anna Lyberopoulou, et al. · Journal of B.U.ON. : official journal of the Balkan Union of Oncology · 7
In vitro effect of hyperthermic Ag and Au Fe3O4 nanoparticles in cancer cells
2019 · Hector Katifelis, Iuliia Mukha, et al. · 4
PDF
Non‐Natural MUC1 Glycopeptide Homogeneous Cancer Vaccine with Enhanced Immunogenicity and Therapeutic Activity
2024 · Ana Guerreiro, Ismael Compañón, et al. · Angewandte Chemie · 2
Works count: 15
Citation count: 86
H-index: 5
I10-index: 4
Year
Topic
Type